Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma

Cancer Causes Control. 2005 Apr;16(3):301-8. doi: 10.1007/s10552-004-3074-9.

Abstract

Regular use of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) has been hypothesized to be associated with reduced risk of non-Hodgkin lymphoma (NHL), although previous results have been inconsistent. The current study investigated the effects of regular aspirin or acetaminophen use on non-Hodgkin lymphoma risk among 625 individuals with primary, incident NHL and 2512 age and sex matched hospital controls with non-neoplastic conditions who completed a comprehensive epidemiologic questionnaire. Results indicate that regular aspirin use may be associated with decreased NHL risk among men [adjusted odds ratio (aOR) 0.82, 95% confidence interval (CI), 0.65--1.04], but not among women (aOR 0.93, 95% CI, 0.71--1.23). In contrast, regular acetaminophen use was associated with elevated NHL risk among women (aOR 1.71, 95% CI, 1.18--2.50) but not among men (aOR 0.75, 95% CI, 0.48--1.17). Other studies have demonstrated that acetaminophen is associated with transient decreases in DNA repair, and lymphocytes may be particularly susceptible to DNA damage, suggesting a mechanism for the elevated NHL risk observed.

MeSH terms

  • Acetaminophen / therapeutic use*
  • Adult
  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Aspirin / therapeutic use*
  • Case-Control Studies
  • DNA Damage
  • DNA Repair
  • Female
  • Humans
  • Incidence
  • Lymphocytes
  • Lymphoma, Non-Hodgkin / epidemiology*
  • Lymphoma, Non-Hodgkin / etiology
  • Lymphoma, Non-Hodgkin / prevention & control*
  • Male
  • Middle Aged
  • Odds Ratio
  • Sex Factors

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Acetaminophen
  • Aspirin